KMT Hepatech, - PhoenixBio Group
Biotechnology Research • 
Edmonton, Alberta, Canada • 11-20 Employees
Company overview
| Headquarters | 2011 94 St NW, Edmonton, Alberta T6N 1H1, CA |
| Phone number | +17806957400 |
| Website | |
| SIC | 873 |
| Founded | 2001 |
| Employees | 11-20 |
| Socials |
Key Contact at KMT Hepatech, - PhoenixBio Group
Masakazu Kakuni
President
KMT Hepatech, - PhoenixBio Group Email Formats
KMT Hepatech, - PhoenixBio Group uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@kmthepatech.com), used 50% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@kmthepatech.com | 50% |
{first name}.{last name} | john.doe@kmthepatech.com | 50% |
About KMT Hepatech, - PhoenixBio Group
KMT Hepatech, Inc. is a part of PhoenixBio group since December 1, 2017 KMT Hepatech provides efficient and cost-effective in vivo research services utilizing platform technology of small animal model, the PXB-Mouse®. The PXB-Mouse® is a chimeric mouse model with humanized liver with stable human hepatocytes engraftment of over 70 per cent. In addition to in vivo services, KMT Hepatech will expand operations and start production of PXB-Cells® - hepatocytes isolated from a PXB-Mouse® liver. Due to the expanding interest in the humanized liver mouse model across a wide range of drug development fields, the company now offers services in the following areas: Infectious diseases, such as Hepatitis C, Hepatitis B and Malaria Safety toxicity: early assessment of potential hepatotoxicity in in vivo settings prior to first-in-human studies Characterization of human-type drug and lipoprotein metabolism in in vivo settings prior to first-in-human studies KMT Hepatech, Inc. owns an international patent portfolio that includes coverage of the uPA chimeric mouse model of HCV infection and on the uPA chimeric mouse for all potential applications including HBV, malaria and studies of toxicity, drug and lipoprotein metabolism. The PXB-Mouse® and PXB-Cells® are your essential tools for therapeutics and vaccine development.
KMT Hepatech, - PhoenixBio Group revenue & valuation
| Annual revenue | $941,105 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $3,100,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
KMT Hepatech, - PhoenixBio Group has 4 employees across 1 departments.
Departments
Number of employees
Funding Data
KMT Hepatech, - PhoenixBio Group has never raised funding before.
KMT Hepatech, - PhoenixBio Group Tech Stack
Discover the technologies and tools that power KMT Hepatech, - PhoenixBio Group's digital infrastructure, from frameworks to analytics platforms.
Security
Hosting
WordPress plugins
Form builders
JavaScript libraries
Page builders
JavaScript libraries
Font scripts
JavaScript libraries
Programming languages
JavaScript libraries
United States
Australia
United Kingdom
South Africa
Italy
FranceFrequently asked questions
4.8
40,000 users
